Features
Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results
Wednesday, December 11 2024 | 10 h 01 min | News,
A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).
CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica
Wednesday, December 11 2024 | 09 h 49 min | News,
CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.
CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions
Wednesday, December 11 2024 | 09 h 24 min | News,
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.
Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™
Wednesday, December 11 2024 | 09 h 10 min | News,
Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory
VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement
Tuesday, December 10 2024 | 09 h 05 min | News,
Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.
Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results
Wednesday, December 11 2024 | 10 h 01 min | News,
A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).
CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica
Wednesday, December 11 2024 | 09 h 49 min | News,
CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.
CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions
Wednesday, December 11 2024 | 09 h 24 min | News,
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.
Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™
Wednesday, December 11 2024 | 09 h 10 min | News,
Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory
VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement
Tuesday, December 10 2024 | 09 h 05 min | News,
Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.
Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results
Wednesday, December 11 2024 | 10 h 01 min | News,
A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).
CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica
Wednesday, December 11 2024 | 09 h 49 min | News,
CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.
CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions
Wednesday, December 11 2024 | 09 h 24 min | News,
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.
Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™
Wednesday, December 11 2024 | 09 h 10 min | News,
Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory
VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement
Tuesday, December 10 2024 | 09 h 05 min | News,
Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.
Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results
Wednesday, December 11 2024 | 10 h 01 min | News,
A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).
CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica
Wednesday, December 11 2024 | 09 h 49 min | News,
CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.
CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions
Wednesday, December 11 2024 | 09 h 24 min | News,
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.
Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™
Wednesday, December 11 2024 | 09 h 10 min | News,
Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory
VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement
Tuesday, December 10 2024 | 09 h 05 min | News,
Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.
